Appendix 4: Commentaries on‘A Quantitative Approach to Benefit–Risk Assessment of Medicines’Pharmacoepidemiology and Drug Safety, 2007, 16

Retracted: A quantitative approach to benefit-risk assessment of medicines–part 2; the practical application of a new model Filip Mussen, Sam Salek, Stuart Walker

Pharmacoepidemiology and Drug Safety ◽

10.1002/pds.1505 ◽

2007 ◽

Vol 16 (10) ◽

pp. 1180-1180 ◽

Cited By ~ 2

Author(s):

Ronald D. Mann

Keyword(s):

Risk Assessment ◽

Quantitative Approach ◽

Practical Application ◽

New Model ◽

Benefit Risk Assessment

Download Full-text

Erratum: A quantitative approach to benefit-risk assessment of medicines — part 2: the practical application of a new model

Pharmacoepidemiology and Drug Safety ◽

10.1002/pds.1460 ◽

2007 ◽

Vol 16 (8) ◽

pp. 946-946 ◽

Cited By ~ 3

Author(s):

Filip Mussen ◽

Sam Salek ◽

Stuart Walker

Keyword(s):

Risk Assessment ◽

Quantitative Approach ◽

Practical Application ◽

New Model ◽

Benefit Risk Assessment

Download Full-text

On a Stepwise Quantitative Approach for Benefit-Risk Assessment

Therapeutic Innovation & Regulatory Science ◽

10.1177/2168479017696274 ◽

2017 ◽

Vol 51 (5) ◽

pp. 625-634 ◽

Cited By ~ 1

Author(s):

Weili He ◽

Yaxuan Sun ◽

Qing Li ◽

Sabrina Wan

Keyword(s):

Risk Assessment ◽

Quantitative Approach ◽

Benefit Risk Assessment

Download Full-text

Retracted:A quantitative approach to benefit-risk assessment of medicines — part 2: the practical application of a new model

Pharmacoepidemiology and Drug Safety ◽

10.1002/pds.1434 ◽

2007 ◽

Vol 16 (S1) ◽

pp. S16-S41 ◽

Cited By ~ 12

Author(s):

Filip Mussen ◽

Sam Salek ◽

Stuart Walker

Keyword(s):

Risk Assessment ◽

Quantitative Approach ◽

Practical Application ◽

New Model ◽

Benefit Risk Assessment

Download Full-text

A quantitative approach to benefit-risk assessment of medicines – part 1: the development of a new model using multi-criteria decision analysis

Pharmacoepidemiology and Drug Safety ◽

10.1002/pds.1435 ◽

2007 ◽

Vol 16 (S1) ◽

pp. S2-S15 ◽

Cited By ~ 72

Author(s):

Filip Mussen ◽

Sam Salek ◽

Stuart Walker

Keyword(s):

Risk Assessment ◽

Decision Analysis ◽

Quantitative Approach ◽

New Model ◽

Multi Criteria Decision Analysis ◽

Benefit Risk Assessment

Download Full-text

A Quantitative Approach for Benefit-Risk Assessment Using Stochastic Multi-Criteria Discriminatory Method

Statistics in Biopharmaceutical Research ◽

10.1080/19466315.2016.1202135 ◽

2016 ◽

Vol 8 (4) ◽

pp. 373-378 ◽

Cited By ~ 3

Author(s):

Yaping Wang ◽

Yabing Mai ◽

Weili He

Keyword(s):

Risk Assessment ◽

Quantitative Approach ◽

Benefit Risk Assessment

Download Full-text

A quantitative approach to benefit-risk assessment of medicines—part 1: the development of a new model using multi-criteria decision analysis; part 2: the practical application of a new model

Pharmacoepidemiology and Drug Safety ◽

10.1002/pds.1436 ◽

2007 ◽

Vol 16 (S1) ◽

pp. S42-S46 ◽

Cited By ~ 12

Author(s):

Filip Mussen ◽

Sam Salek ◽

Stuart Walker

Keyword(s):

Risk Assessment ◽

Decision Analysis ◽

Quantitative Approach ◽

Practical Application ◽

New Model ◽

Multi Criteria Decision Analysis ◽

Benefit Risk Assessment

Download Full-text

The Brighton Collaboration standardized templates for collection of key information for benefit-risk assessment of vaccines by technology (BRAVATO; formerly V3SWG)

Vaccine ◽

10.1016/j.vaccine.2020.10.072 ◽

2020 ◽

Author(s):

Robert T. Chen ◽

Sonali Kochhar ◽

Richard Condit

Keyword(s):

Risk Assessment ◽

Benefit Risk Assessment

Download Full-text

Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase 1/2 Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung Cancer

Clinical Pharmacology & Therapeutics ◽

10.1002/cpt.2228 ◽

2021 ◽

Author(s):

Joseph Chen ◽

Ana Ruiz‐Garcia ◽

Leonard P. James ◽

Gerson Peltz ◽

Holger Thurm ◽

...

Keyword(s):

Lung Cancer ◽

Risk Assessment ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase 1 ◽

Small Cell ◽

Small Cell Lung ◽

Safety And Efficacy ◽

Exposure Response ◽

Benefit Risk Assessment

Download Full-text

Clinical Benefit‐Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors

The Journal of Clinical Pharmacology ◽

10.1002/jcph.1821 ◽

2021 ◽

Author(s):

Jennifer Sheng ◽

Jason Zhang ◽

Christine Baudelet ◽

Amit Roy

Keyword(s):

Risk Assessment ◽

Solid Tumors ◽

Clinical Benefit ◽

Chinese Patients ◽

Benefit Risk Assessment

Download Full-text